10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||||||||||||||
| ||||||||||||||
|
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
ABBOTT LABORATORIES | |||
Ticker: ABT Fiscal Year: 2011 | |||
Consolidated Statement of Earnings | |||
Period Ending Dec 31, 2011 10-K (Filed: Feb 21, 2012) | |||
| (In Millions, except shares in Thousands) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2011 | Dec 31, 2010 | Dec 31, 2009 | |
| Net Sales | $ 38,851 | 35,167 | 30,765 |
| Cost of products sold | 15,541 | 14,665 | 13,209 |
| Research and development | 4,129 | 3,724 | 2,744 |
| Acquired in process and collaborations research and development | 672 | 313 | 170 |
| Selling, general and administrative | 12,757 | 10,376 | 8,406 |
| Total Operating Cost and Expenses | 33,099 | 29,079 | 24,529 |
| Operating Earnings | 5,752 | 6,088 | 6,236 |
| Interest expense | 530 | 553 | 520 |
| Interest (income) | (85) | (105) | (138) |
| Net foreign exchange (gain) loss | (50) | (11) | 36 |
| Other (income) expense, net | 159 | (62) | (1,375) |
| Earnings Before Taxes | 5,199 | 5,713 | 7,194 |
| Taxes on Earnings | 470 | 1,087 | 1,448 |
| Net Earnings | 4,728 | 4,626 | 5,746 |
| Basic Earnings Per Common Share (in dollars per share) | 3.03 | 2.98 | 3.71 |
| Diluted Earnings Per Common Share (in dollars per share) | 3.01 | 2.96 | 3.69 |
| Average Number of Common Shares Outstanding Used for Basic Earnings Per Common Share (in shares) | 1,557,643 | 1,546,400 | 1,546,983 |
| Dilutive Common Stock Options and Awards (in shares) | 9,746 | 9,622 | 8,143 |
| Average Number of Common Shares Outstanding Plus Dilutive Common Stock Options and Awards (in shares) | 1,567,389 | 1,556,022 | 1,555,126 |
| Outstanding Common Stock Options Having No Dilutive Effect (in shares) | 26,789 | 29,403 | 66,189 |
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
ABBOTT LABORATORIES | |||
Ticker: ABT Fiscal Year: 2011 | |||
Consolidated Statement of Comprehensive Income | |||
Period Ending Dec 31, 2011 10-K (Filed: Feb 21, 2012) | |||
| (In Thousands, except shares in actual) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2011 | Dec 31, 2010 | Dec 31, 2009 | |
| Net Earnings | $ 4,728,449 | 4,626,172 | 5,745,838 |
| Foreign currency translation (loss) gain adjustments | (817,539) | (2,290,256) | 2,295,757 |
| Net actuarial (losses) and prior service cost and credits and amortization of net actuarial losses and prior service cost and credits, net of taxes of $(391,528) in 2011, $(70,389) in 2010 and $8,125 in 2009 | (510,444) | (59,447) | (259,814) |
| Unrealized gains on marketable equity securities, net of taxes of $8,338 in 2011, $61 in 2010 and $3,949 in 2009 | 14,442 | 106 | 6,842 |
| Net adjustments for derivative instruments designated as cash flow hedges, net of taxes of $19,857 in 2011 and $20,567 in 2010 | 83,202 | 128,677 | (24,872) |
| Other Comprehensive (loss) income | (1,230,339) | (2,220,920) | 2,017,913 |
| Comprehensive Income | 3,498,110 | 2,405,252 | 7,763,751 |
| Supplemental Accumulated Other Comprehensive Income Information, net of tax as of December 31: | |||
| Cumulative foreign currency translation loss (gain) adjustments | 72,527 | (745,012) | (3,035,268) |
| Net actuarial losses and prior service cost and credits | 2,730,619 | 2,220,175 | 2,160,728 |
| Cumulative unrealized (gains) on marketable equity securities | (38,429) | (23,987) | (23,881) |
| Cumulative (gains) losses on derivative instruments designated as cash flow hedges | (167,532) | (84,330) | 44,347 |
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
ABBOTT LABORATORIES | |||
Ticker: ABT Fiscal Year: 2011 | |||
Consolidated Statement of Cash Flows | |||
Period Ending Dec 31, 2011 10-K (Filed: Feb 21, 2012) | |||
| (In Thousands, except shares in actual) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2011 | Dec 31, 2010 | Dec 31, 2009 | |
| Cash Flow From (Used in) Operating Activities: | |||
| Net earnings | $ 4,728,449 | 4,626,172 | 5,745,838 |
| Adjustments to reconcile earnings to net cash from operating activities | |||
| Depreciation | 1,395,371 | 1,207,450 | 1,210,977 |
| Amortization of intangible assets | 1,648,523 | 1,416,855 | 878,533 |
| Derecognition of a contingent liability associated with the conclusion of the TAP Pharmaceutical Products Inc. joint venture | (797,130) | ||
| Share-based compensation | 382,602 | 387,183 | 366,357 |
| Acquired in-process and collaborations research and development | 672,500 | 313,200 | 170,000 |
| Investing and financing (gains) losses, net | 141,565 | 126,337 | 41,967 |
| Trade receivables | (670,152) | (394,665) | (387,749) |
| Inventories | (129,621) | 139,857 | 230,555 |
| Prepaid expenses and other assets | 413,266 | 553,145 | (386,889) |
| Trade accounts payable and other liabilities | 1,789,652 | 572,533 | (374,715) |
| Income taxes | (1,402,078) | (212,086) | 577,416 |
| Net Cash From Operating Activities | 8,970,077 | 8,735,981 | 7,275,160 |
| Cash Flow From (Used in) Investing Activities: | |||
| Acquisitions of businesses and technologies, net of cash acquired | (672,500) | (9,433,243) | (2,370,630) |
| Acquisitions of property and equipment | (1,491,500) | (1,015,075) | (1,089,048) |
| Purchases of investment securities | (5,109,987) | (805,932) | (248,970) |
| Proceeds from sales of investment securities | 5,648,720 | 954,361 | 16,306 |
| Release of (deposit of) restricted funds | 1,870,000 | (1,870,000) | |
| Other | 16,099 | (18,426) | (6,368) |
| Net Cash From (Used in) Investing Activities | 260,832 | (12,188,315) | (3,698,710) |
| Cash Flow From (Used in) Financing Activities: | |||
| (Repayments of) proceeds from issuance of short-term debt and other | (1,964,685) | (203,854) | 3,217,331 |
| Proceeds from issuance of long-term debt and debt with maturities over 3 months | 1,000,000 | 4,000,000 | 3,000,000 |
| Repayments of long-term debt and debt with maturities over 3 months | (3,012,426) | (1,673,998) | (2,483,176) |
| Purchases of common shares | (77,007) | (866,825) | (826,345) |
| Proceeds from stock options exercised, including income tax benefit | 968,759 | 328,411 | 508,669 |
| Dividends paid | (2,938,096) | (2,671,475) | (2,414,460) |
| Net Cash (Used in) From Financing Activities | (6,023,455) | (1,087,741) | 1,002,019 |
| Effect of exchange rate changes on cash and cash equivalents | (43,005) | (620,893) | 118,848 |
| Net Increase (Decrease) in Cash and Cash Equivalents | 3,164,449 | (5,160,968) | 4,697,317 |
| Cash and Cash Equivalents, Beginning of Year | 3,648,371 | 8,809,339 | |
| Cash and Cash Equivalents, End of Year | 6,812,820 | 3,648,371 | 8,809,339 |
| Supplemental Cash Flow Information: | |||
| Income taxes paid | 1,781,602 | 809,710 | 635,445 |
| Interest paid | 544,559 | 580,168 | 514,326 |
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||
ABBOTT LABORATORIES | ||
Ticker: ABT Fiscal Year: 2011 | ||
Consolidated Balance Sheet | ||
Period Ending Dec 31, 2011 10-K (Filed: Feb 21, 2012) | ||
| (In Thousands, except shares in actual) | ||
| As of | As of | |
| Dec 31, 2011 | Dec 31, 2010 | |
| Current Assets: | ||
| Cash and cash equivalents | $ 6,812,820 | 3,648,371 |
| Investments, primarily time deposits and certificates of deposit | 1,284,539 | 1,803,079 |
| Restricted funds, primarily U.S. treasury bills | 1,872,490 | |
| Trade receivables, less allowances of - 2011: $420,579; 2010: $388,564; 2009: $311,546 | 7,683,920 | 7,184,034 |
| Inventories: | ||
| Finished products | 2,220,527 | 2,058,735 |
| Work in process | 432,358 | 383,580 |
| Materials | 631,364 | 746,419 |
| Total inventories | 3,284,249 | 3,188,734 |
| Deferred income taxes | 2,700,540 | 3,076,051 |
| Other prepaid expenses and receivables | 2,002,706 | 1,544,770 |
| Total Current Assets | 23,768,774 | 22,317,529 |
| Investments | 378,225 | 302,049 |
| Property and Equipment, at Cost: | ||
| Land | 633,917 | 648,988 |
| Buildings | 4,467,387 | 4,334,236 |
| Equipment | 12,216,388 | 11,813,618 |
| Construction in progress | 698,873 | 577,460 |
| Property and Equipment, at Cost | 18,016,565 | 17,374,302 |
| Less: accumulated depreciation and amortization | 10,142,610 | 9,403,346 |
| Net Property and Equipment | 7,873,955 | 7,970,956 |
| Intangible Assets, net of amortization | 9,989,636 | 12,151,628 |
| Goodwill | 15,705,380 | 15,930,077 |
| Deferred Income Taxes and Other Assets | 2,560,923 | 1,901,613 |
| Total Assets | 60,276,893 | 60,573,852 |
| Liabilities and Shareholders' Investment | ||
| Current Liabilities: | ||
| Short-term borrowings | 2,347,859 | 4,349,796 |
| Trade accounts payable | 1,721,127 | 1,535,759 |
| Salaries, wages and commissions | 1,260,121 | 1,328,665 |
| Other accrued liabilities | 7,854,994 | 6,014,772 |
| Dividends payable | 754,284 | 680,749 |
| Income taxes payable | 514,947 | 1,307,723 |
| Current portion of long-term debt | 1,026,896 | 2,044,970 |
| Total Current Liabilities | 15,480,228 | 17,262,434 |
| Long-term Debt | 12,039,822 | 12,523,517 |
| Post-employment Obligations and Other Long-term Liabilities | 8,230,698 | 8,022,770 |
| Commitments and Contingencies | ||
| Shareholders' Investment: | ||
| Preferred shares, one dollar par value Authorized - 1,000,000 shares, none issued | ||
| Common shares, without par value Authorized - 2,400,000,000 shares Issued at stated capital amount - Shares: 2011: 1,638,870,201; 2010: 1,619,689,876; 2009: 1,612,683,987 | 9,817,134 | 8,744,703 |
| Common shares held in treasury, at cost - Shares: 2011: 68,491,382; 2010: 72,705,928; 2009: 61,516,398 | (3,687,478) | (3,916,823) |
| Earnings employed in the business | 20,907,362 | 19,215,768 |
| Accumulated other comprehensive income (loss) | (2,597,185) | (1,366,846) |
| Total Abbott Shareholders' Investment | 24,439,833 | 22,676,802 |
| Noncontrolling Interests in Subsidiaries | 86,312 | 88,329 |
| Total Shareholders' Investment | 24,526,145 | 22,765,131 |
| Total Liabilities and Shareholders' Investment | 60,276,893 | 60,573,852 |
| External Links | |
| ABBOTT LABORATORIES (ABT) Fiscal Year 2011 | |
| Statements of 10-K in Excel | https://www.sec.gov/.../Financial.xlxs |
| Complete 10-K in HTML | https://www.sec.gov/.../10-K.html |
| Complete 10-K in XBRL | https://www.sec.gov/.../10-K-xbrl.zip |